FindTrial
Sign In

Analysis for mechanism of emerging the extremely high tolerance mutations against NS5A inhibitor in genotype 1b HCV after failing to DAAs

Analysis for mechanism of emerging the extremely high tolerance mutations against NS5A inhibitor in genotype 1b HCV after failing to DAAs - Analysis for mechanism of emerging the extremely high tolerance mutations against NS5A inhibitor in genotype 1b HCV after failing to DAAs

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000028842
Enrollment
10
Registered
2017-09-01
Start date
2017-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Sponsors

Saitama Medical University Department of Gastroenterology & Hepatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with genotype 1b HCV of genotype 1b with NS5A-P29del or P32del after failing to DAAs therapy. 2.Patients who have consent acquired for secondary use of preserved serum.

Exclusion criteria

Exclusion criteria: Patients who offers to decline participation in this study

Design outcomes

Primary

MeasureTime frame
genetic analysis for HCV after failing to DAA therapy—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026